

Docket No. 67705/JPW/GJG/ML

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Eran Blaugrund et al.

Serial No.: 10/712,958 Examiner: J. Kim

Filed: November 13, 2003 Group Art Unit: 1617

For : USE OF RASAGILINE WITH OR WITHOUT RILUZOLE TO

TREAT AMYOTROPHIC LATERAL SCLEROSIS

1185 Avenue of the Americas New York, New York 10036 May 8, 2008

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

## FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT ACCOMPANIED BY A STATEMENT UNDER 37 C.F.R. §1.97(e) AND A FEE SET FORTH IN 37 C.F.R. §1.17(p)

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following documents which are listed on Form PTO-1449 (Exhibit A) and are also listed below.

This Supplemental Information Disclosure Statement is being submitted pursuant to 37 C.F.R. §1.97(d) after the mailing date of a Notice of Allowance. Pursuant to 37 C.F.R. §1.97(d), documents submitted after the mailing date of a Notice of Allowance shall be considered if accompanied by a statement under 37 C.F.R. §1.97(e) and the fee set forth in 37 C.F.R. §1.17(p). Pursuant to 37 C.F.R. §1.97(e)(1), the undersigned states that items 1 and 2 listed below were first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Fourth Supplemental Information Disclosure Statement. Specifically, items 1 and 2 below were cited in the supplementary European

Applicants: Eran Blaugrund et al.

Serial No.: 10/712,958

Filed: November 13, 2003

Page 2

Search Report completed April 8, 2008 in connection with European Application No. 03783422.3, which is the counterpart of the subject application. A copy of the Search Report is enclosed as **Exhibit 2**. Pursuant to 37 C.F.R. §1.17(p), the fee for filing this Fourth Information Disclosure Statement is ONE HUNDRED AND EIGHTY DOLLARS (\$180.00) and a check covering this amount is enclosed.

Reference item 1 is a U.S. patent. Pursuant to 37 C.F.R. 1.98(a)(2), a copy of reference item 1 is not being submitted.

Copies of the documents listed below as items 2 and 3 are attached hereto as **Exhibits 1 and 2**, respectively.

- 1. U.S. Patent No. 5,527,814, issued June 18, 1996 (Louvel Erik);
- Naoi, M. et al. "Mitochondrial permeability transition pores: a target of apoptosis regulation by rasagiline", Abstracts of the society for neuroscience, Society for Neuroscience, Washington, DC, US, Vol. 27, No. 1, page 520, XP001189217 (Exhibit 1); and
- Supplemental European Search Report of European Application
   No. EP 03 78 3422, date of completion April 8, 2008 (Exhibit
   2).

Applicants request that the Examiner review the references and make them of record in the subject application.

If a telephone interview would be of assistance in advancing prosecution of the subject application, Applicants' undersigned attorneys invite the Examiner to telephone at the number provided below.

Applicants: Eran Blaugrund et al.

Serial No.: 10/712,958

Filed November 13, 2003

Page 3

No fee, other than the \$180.00 for filing this Fourth Information Disclosure Statement, is deemed necessary. However, if any other fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

certify this that hereby correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

Reg. No. 18,678 Gary J. Gershik 28,678

Reg. No.

John R. White

Registration No. 28,678

Gary J. Gershik

Registration No. 39,992

Attorneys for Applicant Cooper & Dunham LLP

1185 Avenue of the Americas

New York, New York 10036 (212) 278-0400

## **EXHIBIT A**

Applicants: Eran Blaugrund et al.

Serial No.: 10/712,958

Filed: November 13, 2003